4月29日 - ** 制药公司百健（Biogen）股价盘前上涨3.6%，报190.01美元
** 该公司公布第一季度调整后 每股 收益 为3.57美元，超出 分析师平均预期的2.77美元——路孚斯数据
** 得益于多发性硬化症药物销售额超出预期，百健季度营收达24.8亿美元，超出分析师平均预期的22.6亿美元
** 受收购相关成本影响，公司将全年调整后每股收益预期从15.25至16.25美元下调至14.25至15.25美元
** 截至上一交易日收盘，该股年内累计上涨4.2%
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.